Join our LinkedIn PATENTSCOPE users Community Group
Feedback
Settings

Settings

Goto Application

326,409 results
Offices all Languages Stemming false Single Family Member true Include NPL false
RSS feed can only be generated if you have a WIPO account

Save query

A private query is only visible to you when you are logged-in and can not be used in RSS feeds

Query Tree

Refine Options

Offices
All
Specify the language of your search keywords
Stemming reduces inflected words to their stem or root form.
For example the words fishing, fished,fish, and fisher are reduced to the root word,fish,
so a search for fisher returns all the different variations
Returns only one member of a family of patents
Include Non-Patent literature in results

Full Query

IC:G01N33/48

Side-by-side view shortcuts

General
Go to Search input
CTRL + SHIFT +
Go to Results (selected record)
CTRL + SHIFT +
Go to Detail (selected tab)
CTRL + SHIFT +
Go to Next page
CTRL +
Go to Previous page
CTRL +
Results (First, do 'Go to Results')
Go to Next record / image
/
Go to Previous record / image
/
Scroll Up
Page Up
Scroll Down
Page Down
Scroll to Top
CTRL + Home
Scroll to Bottom
CTRL + End
Detail (First, do 'Go to Detail')
Go to Next tab
Go to Previous tab

Analysis

1 / 32,641
1.WO/2024/097357A HIGH-THROUGHPUT LOW-DENSITY LIPOPROTEIN CHOLESTEROL LEVEL SCREENING METHOD
WO - 10.05.2024
Int.Class G01N 33/92
GPHYSICS
01MEASURING; TESTING
NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
33Investigating or analysing materials by specific methods not covered by groups G01N1/-G01N31/131
48Biological material, e.g. blood, urine; Haemocytometers
50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
92involving lipids, e.g. cholesterol
 Appl.No PCT/US2023/036701 Applicant WISCONSIN ALUMNI RESEARCH FOUNDATION Inventor BAKER, Mei
Described herein is a method of extracting and quantitating low density lipoprotein cholesterol (LDL-C) in a blood sample. The sample is first diluted or rehydrated in a reagent 1 to provide a diluted sample. The diluted sample is then mixed with an aqueous reagent 2 including an LDL-C protecting agent, a cholesterol esterase enzyme, a cholesterol oxidase enzyme, and optionally a peroxidase for a time and temperature to degrade non-LDL cholesterol while maintaining LDL-C to provide a reacted sample comprising the LDL-C. The LDL-C is then extracted from the reacted sample by mixing a volume of the reacted sample with a reagent 3 including a water-immiscible organic liquid an internal standard and removing the water-immiscible organic liquid phase sample including the LDL-C and the internal standard (IS). The cholesterol and esters are separated and area of areas of sample LDL-free cholesterol, sample LDL cholesterol esters, free cholesterol internal standard and cholesterol esters internal standard are determined by liquid chromatography-tandem mass spectrometry (LC-MS/MS). Finally, total LDL-C is quantitated.
2.WO/2024/094597METHOD OF PREPARATION OF AMYLOIDOGENIC PROTEIN AGGREGATES AND USES THEREOF
WO - 10.05.2024
Int.Class C07K 14/47
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
14Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
435from animals; from humans
46from vertebrates
47from mammals
 Appl.No PCT/EP2023/080193 Applicant ECOLE POLYTECHNIQUE FEDERALE DE LAUSANNE (EPFL) Inventor LIMORENKO, Galina
The invention relates to methods for the preparation of method of preparation of Tau aggregates, including fibrils, fibrillar species, soluble and insoluble oligomeric species, new Tau aggregates and uses thereof. The invention further relates to the uses of the method of preparation of the so generated Tau aggregates for the identification and screening of modulators of Tau aggregation.
3.WO/2024/096007INHIBITOR FOR GLUCOSE UPTAKE INTO RED BLOOD CELLS, SUPPRESSANT FOR GLUCOSE CONCENTRATION REDUCTION IN BLOOD-COLLECTING TUBE, AND BLOOD-COLLECTING TUBE INCLUDING SAME
WO - 10.05.2024
Int.Class G01N 33/66
GPHYSICS
01MEASURING; TESTING
NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
33Investigating or analysing materials by specific methods not covered by groups G01N1/-G01N31/131
48Biological material, e.g. blood, urine; Haemocytometers
50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
66involving blood sugars, e.g. galactose
 Appl.No PCT/JP2023/039256 Applicant THE UNIVERSITY OF TOKYO Inventor KUME Yukio
The purpose of the present invention is to provide: an inhibitor of glucose uptake into red blood cells; and a blood-collecting tube which suppresses glucose concentration reduction. The present invention provides an inhibitor of glucose uptake into red blood cells, the inhibitor containing inosine as an active ingredient. The inhibitor according to the present invention can be used to suppress a reduction in the glucose concentration in the whole blood collected in a blood-collecting tube. Moreover, the present invention provides a blood-collecting tube including inosine in the internal space thereof. The blood-collecting tube according to the present invention can be used to measure the glucose concentration in the blood. The blood-collecting tube according to the present invention may further include a glycolytic inhibitor.
4.WO/2024/092318DEVICE AND METHOD FOR EVALUATING MALE FERTILITY
WO - 10.05.2024
Int.Class G01N 33/487
GPHYSICS
01MEASURING; TESTING
NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
33Investigating or analysing materials by specific methods not covered by groups G01N1/-G01N31/131
48Biological material, e.g. blood, urine; Haemocytometers
483Physical analysis of biological material
487of liquid biological material
 Appl.No PCT/AU2023/051110 Applicant ROYAL MELBOURNE INSTITUTE OF TECHNOLOGY Inventor CASTRO, Jasmine
A method and device for evaluating male fertility in a human or animal subject are provided. The device includes an acoustically-driven microfluidic rheometry instrument; a detector; and a processing device. The processing device is configured to determine thread thinning dynamics of a semen sample obtained from the subject, the thread thinning dynamics being determined using the instrument, wherein the thread thinning dynamics of the semen sample provide at least one measure indicative of a quality of sperm in the semen sample; compare the at least one measure with a minimum threshold reference value for determining male fertility in a human or animal subject; and evaluate fertility of the semen sample obtained from the subject based on the at least one measure.
5.WO/2024/095648MEASUREMENT METHOD, MEASUREMENT SYSTEM AND TEST REAGENT KIT
WO - 10.05.2024
Int.Class G01N 33/49
GPHYSICS
01MEASURING; TESTING
NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
33Investigating or analysing materials by specific methods not covered by groups G01N1/-G01N31/131
48Biological material, e.g. blood, urine; Haemocytometers
483Physical analysis of biological material
487of liquid biological material
49blood
 Appl.No PCT/JP2023/035443 Applicant HORIBA, LTD. Inventor MANIO Mark Christian Carizon
A measurement method for determining the concentration of reticulocytes or nucleated red blood cells contained in a blood specimen, the measurement method including a staining step, a removal step and a measurement step. In the staining step, reticulocytes or nucleated red blood cells, among red blood cells contained in the blood specimen, are stained. In the removal step, a surfactant is added to the blood specimen to take out hemoglobin from the red blood cells. In the measurement step, the concentration of the reticulocytes or nucleated red blood cells contained in the blood specimen is determined using the blood specimen after the staining and removal steps.
6.WO/2024/097313METHODS FOR PRODUCING T CELL THERAPY PRODUCTS
WO - 10.05.2024
Int.Class A61K 39/00
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
39Medicinal preparations containing antigens or antibodies
 Appl.No PCT/US2023/036627 Applicant SANA BIOTECHNOLOGY, INC. Inventor JOHNSON, Adam James
Methods of profiling cells for donor capability with a recipient subject are provided. In particular, methods relating to identifying cells, such as T cells, suitable for making a cell therapy product and administration to a patient (e.g., as CAR T cell therapy). Methods are also provided of profiling the donor capability of a cell or population of cells for cell therapy, such methods comprising evaluating the cell or the population of cells for predicted function. A predicted cell function may be evaluated by assaying one or more cell parameters. Further, cells and cell therapy products manufactured according to such methods are provided.
7.WO/2024/097388SYSTEMS AND METHODS FOR MONITORING FATTY ACID METABOLISM
WO - 10.05.2024
Int.Class A61B 5/00
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
BDIAGNOSIS; SURGERY; IDENTIFICATION
5Measuring for diagnostic purposes; Identification of persons
 Appl.No PCT/US2023/036748 Applicant ARIZONA BOARD OF REGENTS ON BEHALF OF THE UNIVERSITY OF ARIZONA Inventor DOYLE, Kristian
The present disclosure relates to methods of determining and administering a treatment course of action. In particular, the present disclosure relates to compositions and methods for monitoring and treating neurological damage (e.g., stroke), for example, with anti-inflammation therapy.
8.WO/2024/096593BIOMARKER DETECTOR, PREPARATION METHOD THEREFOR, AND BIOMARKER DETECTION METHOD
WO - 10.05.2024
Int.Class G01N 27/327
GPHYSICS
01MEASURING; TESTING
NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
27Investigating or analysing materials by the use of electric, electro-chemical, or magnetic means
26by investigating electrochemical variables; by using electrolysis or electrophoresis
28Electrolytic cell components
30Electrodes, e.g. test electrodes; Half-cells
327Biochemical electrodes
 Appl.No PCT/KR2023/017307 Applicant RESEARCH ＆ BUSINESS FOUNDATION SUNGKYUNKWAN UNIVERSITY Inventor YUN, Wan Soo
Provided is a preparation method for a biomarker detector, including the steps of: preparing a reactant that chemically reacts with a biomarker; and dissolving the reactant in an acceleration solution including an accelerator for accelerating a chemical reaction between the reactant and the biomarker, to prepare a biomarker detector.
9.WO/2024/098003METHODS FOR DETECTION OF CELL-FREE DNA (CFDNA) AND USES THEREOF FOR DIAGNOSING, TREATING, AND/OR MONITORING ALZHEIMER'S DISEASE
WO - 10.05.2024
Int.Class G01N 33/68
GPHYSICS
01MEASURING; TESTING
NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
33Investigating or analysing materials by specific methods not covered by groups G01N1/-G01N31/131
48Biological material, e.g. blood, urine; Haemocytometers
50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
68involving proteins, peptides or amino acids
 Appl.No PCT/US2023/078701 Applicant SEQ BIOMARQUE, LLC Inventor BACUS, Sarah
Provided herein are biomarkers present in cell-free DNA (cfDNA) for the early detection of pre-clinical Alzheimer's Disease (AD), mild cognitive impairment (MCI), or AD in a subject. The detection of such biomarkers in a subject may be used to inform methods of treating a subject with a therapy (e.g., a drug or biologic) for pre-clinical Alzheimer's Disease (AD), mild cognitive impairment (MCI), or AD. The biomarkers disclosed herein may also be used in methods to monitor the progression of pre-clinical AD, MCI, or AD.
10.WO/2024/097892REGULATION OF ARTIFICIAL MIRNAS BY ENDOGENOUS TISSUE-SPECIFIC MIRNAS AND METHODS OF USING THE SAME
WO - 10.05.2024
Int.Class A61K 31/711
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
70Carbohydrates; Sugars; Derivatives thereof
7088Compounds having three or more nucleosides or nucleotides
711Natural deoxyribonucleic acids, i.e. containing only 2'-deoxyriboses attached to adenine, guanine, cytosine or thymine and having 3'-5' phosphodiester links
 Appl.No PCT/US2023/078541 Applicant MIRIMUS, INC. Inventor MILITELLO, Giuseppe
This disclosure relates to introducing specified endogenous amiRNA responsive to endogenous primary-miRNAs. This invention allows the degradation of amiRNAs in specific tissues, while allowing amiRNA to silence gene expression in other tissues. No studies or publications have been found describing a similar approach. Any available amiRNA could be modified and any endogenous miRNA could be used as regulator. The invention is highly modifiable and tunable. The experimental validation pipeline is optimized to enable the discovery of the most functional design. This is done through modifying the loop of a given amiRNA to make it complementary to potentially any endogenous miRNA.
# -